Literature DB >> 14636356

Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children.

Christina A Gurnett1, Michael Landt, Michael Wong.   

Abstract

PURPOSE: To evaluate pediatric seizure patients for astrocytic injury by measuring cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP), determine risk factors for GFAP elevation after seizures, and compare seizure-induced astrocyte injury with neuronal injury by concurrent measurement of CSF neuron-specific enolase (NSE).
METHODS: CSF obtained from pediatric patients (n = 52) within 24 h of seizure was assayed for GFAP and NSE. Retrospective chart review was performed for seizure type, duration, and etiology.
RESULTS: Overall, children with seizures had elevated CSF GFAP compared with controls (p = 0.0075), but no elevation of NSE (p = 0.1437). No effect of seizure type or etiology was found, but a significant positive effect of seizure duration (p = 0.0010) and status epilepticus (p = 0.0296) was seen on CSF GFAP. Individually, seven children (13%) had elevated GFAP (>440 pg/ml); in five children, the increased GFAP was not accompanied by elevations in NSE (<12 ng/ml). Five children with elevated GFAP had symptomatic etiologies for their seizures, but the etiology of one child with elevated GFAP was cryptogenic, and one had febrile seizures.
CONCLUSIONS: Elevation of CSF GFAP after seizures suggests that astrocytic injury may occur in a subgroup of children, primarily in the context of prolonged seizures and symptomatic etiologies. Increased GFAP levels may occur in patients with normal NSE, suggesting that GFAP may be a more sensitive marker of brain injury in some cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636356     DOI: 10.1046/j.1528-1157.2003.21603.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

1.  Degeneration and proliferation of astrocytes in the mouse dentate gyrus after pilocarpine-induced status epilepticus.

Authors:  Karin Borges; Dayna McDermott; Hasan Irier; Yoland Smith; Raymond Dingledine
Journal:  Exp Neurol       Date:  2006-06-21       Impact factor: 5.330

2.  Cellular injury and neuroinflammation in children with chronic intractable epilepsy.

Authors:  Jieun Choi; Douglas R Nordli; Tord D Alden; Arthur DiPatri; Linda Laux; Kent Kelley; Joshua Rosenow; Stephan U Schuele; Veena Rajaram; Sookyong Koh
Journal:  J Neuroinflammation       Date:  2009-12-19       Impact factor: 8.322

Review 3.  The Ictal-Interictal Continuum: To Treat or Not to Treat (and How)?

Authors:  Clio Rubinos; Alexandra S Reynolds; Jan Claassen
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

4.  Changes of biochemical biomarkers in the serum of children with convulsion status epilepticus: a prospective study.

Authors:  Manli Wang; Jian Yu; Xiao Xiao; Bingbing Zhang; Jihong Tang
Journal:  BMC Neurol       Date:  2022-05-27       Impact factor: 2.903

5.  Rapamycin Attenuates Acute Seizure-induced Astrocyte Injury in Mice in Vivo.

Authors:  Dongjun Guo; Jia Zou; Michael Wong
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

6.  Pro-inflammatory cytokines, but not brain- and extracellular matrix-derived proteins, are increased in the plasma following electrically induced kindling of seizures.

Authors:  Natalia Chmielewska; Piotr Maciejak; Bartosz Osuch; Miron B Kursa; Janusz Szyndler
Journal:  Pharmacol Rep       Date:  2020-12-30       Impact factor: 3.024

7.  A Meta-Analysis of Neuron-Specific Enolase Levels in Cerebrospinal Fluid and Serum in Children With Epilepsy.

Authors:  Rong-Zheng Mu; Shuang Liu; Kai-Ge Liang; Dan Jiang; Yao-Jiang Huang
Journal:  Front Mol Neurosci       Date:  2020-03-10       Impact factor: 5.639

8.  Promising candidate cerebrospinal fluid biomarkers of seizure disorder, infection, inflammation, tumor, and traumatic brain injury in pediatric patients.

Authors:  Seh Hyun Kim; Soo Ahn Chae
Journal:  Clin Exp Pediatr       Date:  2021-08-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.